Dergiler / Türk Doğa ve Fen Dergisi / 2026 / Sayı: 1 Özel Sayı

Determination of Pharmacokinetic and Toxicological Parameters of Some Commonly Used Statin Group Drugs

Mustafa Tuğfan Bilkan(TOKAT GAZİOSMANPAŞA ÜNİVERSİTESİ)0000-0002-0306-1509
Çiğdem Bilkan(TOKAT GAZİOSMANPAŞA ÜNİVERSİTESİ)0000-0002-3347-673X
Sayfa
69–72
Yayın Tarihi
2024-10-01
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Accordingly, it is recommended that the consequences of using pravastatin and atorvastatin, cholesterol drugs with lower toxicity classes, should be investigated more seriously in terms of minimum toxic substance intake for patient groups requiring high doses of medication.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Statins work as inhibitors of the HMG-CoA reductase enzyme and are the most commonly prescribed cholesterol-lowering drug group for people with cardiovascular disease or risk.
📊
Temel Bulgular & Veri:The study results showed that the toxicity classifications of the drugs were 5 (LD: 5000 mg/kg) for atorvastatin and 6 (LD: 8939 mg/kg) for pravastatin, respectively.
💡
Sonuç & Katkı:Accordingly, it is recommended that the consequences of using pravastatin and atorvastatin, cholesterol drugs with lower toxicity classes, should be investigated more seriously in terms of minimum toxic substance intake for patient groups requiring high doses of medication.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Statin group drugs · Molecular modeling · In silico investigations

Abstract

Statins work as inhibitors of the HMG-CoA reductase enzyme and are the most commonly prescribed cholesterol-lowering drug group for people with cardiovascular disease or risk. This study aimed to determine the pharmacokinetic parameters and toxicities of conventional and new-generation cholesterol drugs such as atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, rosuvastatin and pitavastatin. Absorption, distribution, metabolism, and excretion (ADME) parameters and toxicity predictions of drugs were made using in silico modeling, which gives faster results than animal experiments and does not involve any laboratory costs. In calculations made using structural similarity, compounds' pharmacokinetic properties and toxicity predictions are obtained based on previously known structure-activity data. The study results showed that the toxicity classifications of the drugs were 5 (LD: 5000 mg/kg) for atorvastatin and 6 (LD: 8939 mg/kg) for pravastatin, respectively. The toxicity classes were found to be 4 for all the other statin group drugs. The results showed that pravastatin had the lowest toxicity among investigated cholesterol drugs, while pitavastatin and fluvastatin had the highest toxic effects. Accordingly, it is recommended that the consequences of using pravastatin and atorvastatin, cholesterol drugs with lower toxicity classes, should be investigated more seriously in terms of minimum toxic substance intake for patient groups requiring high doses of medication.

🔖

Bu Makaleye Atıf Yap

Bilkan, M. T., Bilkan, Ç. (2024). Determination of Pharmacokinetic and Toxicological Parameters of Some Commonly Used Statin Group Drugs. Türk Doğa ve Fen Dergisi, Sayı: 1 Özel Sayı, 69–72. https://doi.org/10.46810/tdfd.1411970

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Civek S. ve Akman M. Dünyada ve Türkiye’de kardiyovasküler hastalıkların sıklığı ve riskin değerlendirilmesi. Jour Turk Fam Phy 2022; 13 (1): 21-28. Doi: 10.15511/tjtfp.22.00121.
  2. Alenghat FJ, Davis AM (February 2019). "Management of Blood Cholesterol". JAMA. 321 (8): 800–801. doi:10.1001/jama.2019.0015. PMC 6679800.
  3. National Clinical Guideline Centre (UK) (July 2014). Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. National Institute for Health and Clinical Excellence: Guidance. London: National Institute for Health and Care Excellence (UK). PMID 25340243. NICE Clinical Guidelines, No. 181 – via NIH National Library of Medicine.
  4. Endo, A. A gift from nature: the birth of the statins. Nat Med 14, 1050–1052 (2008). https://doi.org/10.1038/nm1008-1050
  5. Sweetman SC, ed. (2009). "Cardiovascular drugs". Martindale: the complete drug reference (36th ed.). London: Pharmaceutical Press. pp. 1155–1434.
  6. MarvinSketch
  7. PreADMET, https://preadmet.qsarhub.com/, (2022).
  8. ProTox-II- Prediction of Toxicity of Chemicals, (2022).
  9. Yong-Jin Wu, Heterocycles and Medicine, Progress in Heterocyclic Chemistry, 2012
  10. https://www.stereoelectronics.org/webDD/DD_05.html
  11. Furuya, Y., Sekine, Y., Kato, H., Miyazawa, Y., Koike, H., & Suzuki, K. (2016). Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins. Prostate international, 4(2), 56-60.
  12. Alan Talevi, Pablo A. M. Quiroga, (2018). ADME Processes in Pharmaceutical Sciences.
  13. Olson, R. E., & Christ, D. D. (1996). Plasma protein binding of drugs. In Annual reports in medicinal chemistry (Vol. 31, pp. 327-336). Academic Press.
  14. Libralato, G., Annamaria, V. G., & Francesco, A. (2010). How toxic is toxic? A proposal for wastewater toxicity hazard assessment. Ecotoxicology and Environmental Safety, 73(7), 1602-1611.
  15. DePass, L. R. (1989). Alternative approaches in median lethality (LD50) and acute toxicity testing. Toxicology letters, 49(2-3), 159-170./